Iridex Corp (IRIX)
NASDAQ:IRIX
Want to see IRIX full AI Analyst Report?
IRIX Stock Chart & Stats
$1.23
-$0.02(-1.39%)
At close: 4:00 PM EST
$1.23
-$0.02(-1.39%)
Day’s Range― - ―
52-Week Range$0.87 - $1.65
Previous CloseN/A
Volume8.51K
Average Volume (3M)66.91K
Market Cap
$19.67M
Enterprise Value$20.05M
Total Cash (Recent Filing)$4.59M
Total Debt (Recent Filing)$4.28M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Aug 06, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding17,406,519
10 Day Avg. Volume69,445
30 Day Avg. Volume66,914
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)4.09
Price to Sales (P/S)0.38
P/FCF Ratio-8.91
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue0.38
Enterprise Value/Gross Profit1.06
Enterprise Value/Ebitda-12.27
Forecast
1Y Price Target
$2.75Price Target Upside123.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$53.00M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Service RevenueA business model with capital equipment placements plus recurring consumable and service revenue creates durable, procedure‑tied cash flows. Over 2–6 months this supports revenue resilience, higher lifetime customer value and predictable replacement cycles that can stabilize margins as installed base grows.
G‑Probe And Cyclo G6 Unit MomentumRapid unit adoption of probes and continued Cyclo G6 revenue growth indicate tangible commercial traction in core glaucoma offerings. Sustained unit growth supports recurring consumable sales, validates product-market fit, and underpins longer‑term installed base expansion and procedure volume-driven revenue.
Cost Reduction Roadmap & Positive Cash Flow GuidanceConcrete, multi‑quarter cost actions and a contract manufacturing shift create a credible path to sustainable margin improvement and self‑funding operations. If executed, these initiatives reduce fixed cost base and manufacturing expense, lowering funding needs and improving long‑term cash generation.
Bears Say
Declining Revenue And Ongoing LossesMaterial TTM revenue decline and persistent net losses reflect structural demand, mix, or competitive pressures that impair scale economics. Continued top‑line shrinkage limits ability to absorb fixed costs, putting pressure on profitability and hindering sustained reinvestment in R&D and commercial expansion.
Weak Cash Generation And Thin Capital BaseNegative operating and free cash flow with a modest cash balance and limited equity cushion raise financing risk if improvements slip. A constrained capital base reduces flexibility to invest, absorb setbacks, or accelerate commercialization, increasing the probability of external funding needs over the medium term.
International Regulatory And Supply HeadwindsRegulatory approvals and supply reliability are structural growth enablers for international expansion. Persistent delays and compliance gaps limit system placements and downstream consumable demand abroad, slowing addressable market growth and creating recurring revenue headwinds until resolved.
Iridex News
IRIX FAQ
What was Iridex Corp’s price range in the past 12 months?
Iridex Corp lowest stock price was $0.87 and its highest was $1.65 in the past 12 months.
What is Iridex Corp’s market cap?
Iridex Corp’s market cap is $19.67M.
When is Iridex Corp’s upcoming earnings report date?
Iridex Corp’s upcoming earnings report date is Aug 06, 2026 which is in 45 days.
How were Iridex Corp’s earnings last quarter?
Iridex Corp released its earnings results on May 19, 2026. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.07 by $0.04.
Is Iridex Corp overvalued?
According to Wall Street analysts Iridex Corp’s price is currently Undervalued.
Does Iridex Corp pay dividends?
Iridex Corp does not currently pay dividends.
What is Iridex Corp’s EPS estimate?
Iridex Corp’s EPS estimate is -0.01.
How many shares outstanding does Iridex Corp have?
Iridex Corp has 17,406,519 shares outstanding.
What happened to Iridex Corp’s price movement after its last earnings report?
Iridex Corp reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.07. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Iridex Corp?
Currently, no hedge funds are holding shares in IRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Iridex Corp
IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.
IRIX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive picture: solid operational progress (probe and Cyclo G6 growth, cost reductions, partnership expansion, and a near‑term $0.8M backlog) balanced against notable international headwinds, a YoY gross margin decline, softer retina system sell‑through, and a quarter‑end cash decline. Management reaffirmed full‑year guidance ($51M–$53M excluding the Middle East), expects full‑year positive operating cash flow, and highlighted multi‑quarter initiatives (G&A relocation and contract manufacturer transition) that should improve margins over time. Near‑term risks are primarily timing and international/regulatory disruptions rather than fundamental demand weakness in core U.S. businesses.View all IRIX earnings summariesIRIX Stock 12 Month Forecast
Average Price Target
$2.75
▲(123.58% Upside)
Technical Analysis
Sintx Technologies
―
PAVmed
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Envoy Medical
―
Ownership Overview
11.09% Insiders
3.60% Mutual Funds
8.02% Other Institutional Investors
74.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---